Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments.
The effect of synthetic human PTHrP (1-34) or (107-111) fragments on bone loss was studied in rats, one month after ovariectomy (OVX). Four groups of 7-8-month-old rats were treated sc daily for 13 d with PTHrP (1-34) or (107-111) at the dose of 1 or 3 nmol/100 g body weight. Sham-operated (SHO) and control OVX rats received solvent alone. In our conditions, at the lowest dose, neither (1-34) nor (107-111) fragments had any significant effect. However, at the dose of 3 nmol/100 g daily for 13 d both treatments significantly increased femoral dry weight, ash weight, Ca content and densitometry of the femur. The effect of PTHrP (1-34) mainly resulted from increased cortical and trabecular bone (% recovery: 98.25 and 105.23%, respectively). For the PTHrP (107-111) fragment, a positive effect was only demonstrated on the cortical bone (98.25% recovery). The results of this study demonstrate that both hPTHrP (1-34) and (107-111, osteostatin) fragments are positive for bone when administered at the dose of 3 nmol/100 g body weight/d for 13 d to adult OVX rats.
Rouffet
J
J
INRA-Theix, Métabolisme Minéral, Saint-Genès-Champanelle, France.
Coxam
V
V
Gaumet
N
N
Barlet
J P
JP
D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000627:therapeutic use; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments; D011506:Proteins; C071784:parathyroid hormone-related protein (107-111); C054296:parathyroid hormone-related protein (1-34)